ArticleOncology letters2025

Erratum: [Corrigendum] Investigating the efficacy of tissue factor pathway inhibitor‑2 as a promising prognostic marker for ovarian cancer.

Tomoka Maehana et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.